BRINGING NOVEL INVESTIGATIONAL TREATMENTS FOR ECZEMA, ASTHMA and cancer ONE STEP CLOSER TO APPROVAL

Clinical trials are an important part of providing new medicines to those who need them. We are currently enrolling participants into multiple clinical trials. Learn more and see if you qualify!
Eczema RPT193
Asthma RPT193
CANCER FLX475
RPT193 for the treatment of eczema (atopic dermatitis)

Study title:

A Phase 2 study to evaluate the efficacy and safety of RPT193 as monotherapy in adults with moderate-to-severe atopic dermatitis

Status:

Enrolling

About the study: This clinical trial is looking at the efficacy (change in EASI scores) and safety of different doses of an oral investigational treatment called RPT193 in people with moderate or severe eczema (also known as atopic dermatitis). Study participants will have either tried and failed to get adequate results with topical treatments (e.g., corticosteroids) or are not able to use topical treatments. RPT193 comes as a pill and is taken by mouth once daily. Treatment will be for 16 weeks. There are approximately 50 study sites throughout the US. There is no cost to participate.

Who can participate:
  • Men and women 18–75 years of age
  • Moderate or severe eczema (atopic dermatitis)
  • Inadequate response to or unable to use topical treatments
  • Other criteria apply; learn more at the link below

EASI = eczema area and severity index.

see if you qualify
RPT193 for the treatment of asthma

Study title:

A Phase 2 study to evaluate the efficacy and safety of RPT193 in adults with moderate-to-severe T2-high asthma who are partially controlled on inhaled corticosteroid and long-acting beta2 agonist therapy

Status:

Enrolling

About the study: This clinical trial is looking at the efficacy and safety of an investigational treatment called RPT193 in people with moderate or severe T2-high asthma, which is a form of asthma that is closely associated with allergic disease. Participants will already be using an inhaled corticosteroid (ICS) and long-acting beta2 agonist (LABA). RPT193 comes as a pill and is taken by mouth once daily. Treatment will be for 14 weeks. There are approximately 12 study sites throughout the US. There is no cost to participate.

Who can participate:
  • Men and women 18–65 years of age
  • Moderate or severe asthma
  • Taking an inhaled corticosteroid (ICS) combined with a long-acting beta2 agonist (LABA)
  • Other criteria apply; learn more at the link below
LEARN MORE AND
VIEW STUDY LOCATIONS
FLX475 FOR THE TREATMENT OF CANCER

RAPT Therapeutics is looking at a potential treatment called FLX475 alone and/or in combination with KEYTRUDA® (pembrolizumab).

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp.

Learn more about the study for people with various types of advanced cancers
LEARN MORE